ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Search through all presentations

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...-marker-based-clinical-decision-making-today

MethodsResultsConclusions

Date: 26 Sep 2014
Presenter: Michael Weller
Resources: Abstract
Topics: Central Nervous System Malignancies, Pathology/Molecular Biology, Personalised Medicine

http://oncologypro.esmo.org/Meeting-Resourc...and-cyclin-D-CDK4-6-pathway-activated-tumors

AimSMARCB1 mutations are observed in the majority of malignant rhabdoid tumors (MRTs) rendering them dependent on cyclin D1 (CCND1) for genesis and survival. Genetic aberrations in CCND1 and CDK4 are frequent in neuroblastoma cell lines.

Date: 27 Sep 2014
Presenter: Birgit Geoerger
Resources: Abstract
Topics: Drug Development, Central Nervous System Malignancies, Sarcoma, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...d-tumors-or-recurrent-high-grade-gliomas-HGG

Aim Background: Without active delivery across the blood-brain barrier, the efficacy of doxorubicin is limited in the treatment of brain tumors. Therefore, 2B3-101 has been developed as a brain-targeted doxorubicin product.

Date: 27 Sep 2014
Presenter: Dieta Brandsma
Resources: Abstract
Topics: Drug Development, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...4/Invited-discussant-abstracts-417O-and-418O

Date: 27 Sep 2014
Presenter: Michael Weller
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies, Personalised Medicine

http://oncologypro.esmo.org/Meeting-Resourc...ited-discussant-abstracts-414O-415O-and-416O

Date: 27 Sep 2014
Presenter: Evanthia Galanis
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...sed-on-the-analysis-of-patient-registry-data

AimTo present updated outcomes and toxicity data from patients with recurrent glioblastoma treated with the commercially available NovoTTF-100A System using patient registry database.

Date: 27 Sep 2014
Presenter: Maciej Mrugala
Resources: Abstract, Presentation, Webcast
Topics: Central Nervous System Malignancies, Translational Research, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-plus-bevacizumab-BEV-.-ClinicalTrials.gov-N

AimWe compared treatment with TMZ versus TMZ + BEV prior to and concomitant with radiotherapy in unresectable GBM p. The potential prognostic role of MGMT methylation was examined in p with available tissue and/or serum samples.

Date: 27 Sep 2014
Presenter: Carmen Balana
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies, Personalised Medicine

http://oncologypro.esmo.org/Meeting-Resourc...19q-co-deleted-and-partially-deleted-gliomas

AimRadiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA).

Date: 27 Sep 2014
Presenter: Mairead McNamara
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies, Personalised Medicine

http://oncologypro.esmo.org/Meeting-Resourc...l-results-from-the-randomized-phase-II-trial

AimThe treatment of recurrent glioblastoma (GBM) remains an open issue and the role of BEV has been largely debated since only few data compared this agent with the standard agents.

Date: 27 Sep 2014
Presenter: Alba Brandes
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...mide-TMZ-in-newly-diagnosed-glioblastoma-GBM

AimDespite standard therapy for GBM, median survival is 1-2 years. Abnormal epidermal growth factor receptor (EGFR) expression and signaling are common in GBM. ABT-414 is a unique antibody-drug conjugate,...

Date: 27 Sep 2014
Presenter: Hui Gan
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies, Surgery and/or Radiotherapy of Cancer